CD47 is an immunoglobulin that is overexpressed on the surface of many types of cancer cells. CD47 forms a signaling complex with signal-regulatory protein α (SIRPα), enabling the escape of these cancer cells from macrophage-mediated phagocytosis. In recent years, CD47 has been shown to be highly expressed by various types of solid tumors and to be associated with poor patient prognosis in various types of cancer. A growing number of studies have since demonstrated that inhibiting the CD47-SIRPα signaling pathway promotes the adaptive immune response and enhances the phagocytosis of tumor cells by macrophages. Improved understanding in this field of research could lead to the development of novel and effective anti-tumor treatments that act through the inhibition of CD47 signaling in cancer cells. In this review, we describe the structure and function of CD47, provide an overview of studies that have aimed to inhibit CD47-dependent avoidance of macrophage-mediated phagocytosis by tumor cells, and assess the potential and challenges for targeting the CD47-SIRPα signaling pathway in anti-cancer therapy.
终于，理论上IVM跟COVID疾病的关联点，一直是不确定的，即便那些支持IVM的医生，他们也是语焉不详。
本文不试图证明IVM有效。神药。只提供观点。
1. COVID重症与CD47 marker的强关联被证明
Protein found on infected cells protects virus from immune systemhttps://www.reuters.com/article/us-health-coronavirus-science-idCAKBN2GN1YC
Cell surface marker CD47 may allow early diagnosis of severe COVID-19https://www.news-medical.net/news/20210304/Cell-surface-marker-CD47-may-allow-early-diagnosis-of-severe-COVID-19.aspx
2. CD47是癌症标配，CD47阻止免疫系统对癌细胞的扫除。
3. 一定意义上说，COVID19是病毒癌症。因为这个病毒不仅掌握的开门的钥匙，还穿上了皇上御赐黄裤衩。
4. CD47的分布密度，与年龄和血压血糖相关。
5. 人民的希望，有助于清除CD47，从而降低COVID重症率。这个新药不仅即刻得到批准，而且被广泛认为有原理上的支持（CD47）
https://www.reuters.com/article/us-health-coronavirus-science-idCAKBN2GN1YC
无独有偶
完全不相干的另一个研究，发表在权威期刊
https://www.nature.com/articles/s41523-021-00229-5
Ivermectin converts cold tumors hot and synergizes with immune checkpoint blockade for treatment of breast cancer什么意思？乳腺癌难以治愈，原因之一就是CD47大量出现在癌细胞上，是的人体免疫自动绕过去，不对它们进行攻击（冷癌症）。
IVM清除CD47，使得癌细胞变成热癌症（hot tumor）。然后人体免疫系统就可以屠杀癌细胞了。
现在揭晓时刻到了。IVM连癌症CD47都能够清除，那么COVID感染后细胞上过多的CD47，也就同样有可能被IVM干掉。中和掉，洗掉。whatever掉。随后，人体的免疫机制就可以恢复正常，吞掉被感染的细胞。从而大幅降低病毒量，减少巨量病毒在体内引发的因子风暴。
于是，本来宿命COVID重症的人（早期）早期服用IVM，就有可能避免病毒“癌"在体内的迅速扩散。从而抑制重症。
这三篇文章，枫林自己找到的，一直很好奇，为什么IVM有可能帮助患者。我自以为，这是其中一个可能的途径。
提供给医学相关的网友，嘲笑和驳斥。
IVM连癌症都能治疗，而且是辅助免疫疗法。 治疗个COVID19，为什么就一定不可能？新冠也是靠CD47，逃过免疫的。
世界上不缺你这块料，，
谁在捣乱，一目了然。
Science is the belief in the ignorance of experts.
通俗讲法就是，科学就是要挑战所谓专家的意见。
FDA 不许Ivermectin用来治疗新冠病人，所以首先须获得FDA授权。。。
链接
但是 WHO advises that ivermectin only be used to treat COVID-19 within clinical trials
链接
各国数据都显示，IVM开始使用后，一般几周内，疫情就会掉头向下（是否有因果关系，我没有数据）
Poison Control Centers Are Fielding A Surge Of Ivermectin Overdose Calls
Two deaths linked to ivermectin in New Mexico
CD4在2020年有不少文章。主要是癌症领域！没想到，COVID19逃过免疫吞噬的机制，竟然和癌症共通。
COVID19，莫名其妙地有了开启人体细胞的钥匙“SPIKE”
COVID19，对某些人（老人，高糖高血压。。。）可以躲过免疫吞噬，剧烈复制，最终太多了触发免疫风暴。杀死宿主。
COVID19的变异能力也是神级的，现在SPIKE可以稍微变化，导致针对SPIKE的防线漏洞百出。
真是病毒之神！
面对神一样的对手，明智的学者不会将鸡蛋都放在SPIKE一个篮子里，风险过高。如果最终出现完全的逃逸，怎么办？应该看看免疫过程的其他环节了！
CD47 is an immunoglobulin that is overexpressed on the surface of many types of cancer cells. CD47 forms a signaling complex with signal-regulatory protein α (SIRPα), enabling the escape of these cancer cells from macrophage-mediated phagocytosis. In recent years, CD47 has been shown to be highly expressed by various types of solid tumors and to be associated with poor patient prognosis in various types of cancer. A growing number of studies have since demonstrated that inhibiting the CD47-SIRPα signaling pathway promotes the adaptive immune response and enhances the phagocytosis of tumor cells by macrophages. Improved understanding in this field of research could lead to the development of novel and effective anti-tumor treatments that act through the inhibition of CD47 signaling in cancer cells. In this review, we describe the structure and function of CD47, provide an overview of studies that have aimed to inhibit CD47-dependent avoidance of macrophage-mediated phagocytosis by tumor cells, and assess the potential and challenges for targeting the CD47-SIRPα signaling pathway in anti-cancer therapy.